We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MSGE:NYSEMadison Square Garden Entertainment Corp. Analysis

Data as of 2026-05-22 - not real-time

$69.37

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Madison Square Garden Entertainment (MSGE) is trading at $69.37, comfortably above its 20‑day SMA of 66.56 and 50‑day SMA of 62.12, while still below the 200‑day SMA of 53.02, indicating a strong bullish bias. The RSI of 67 and a bullish MACD histogram reinforce short‑term momentum, but the stock sits near its 52‑week high of $70.81, suggesting limited upside in the immediate term. Volume is on an upward trend, and the 30‑day volatility of 26% combined with a beta of 0.93 points to price swings that could test the $59.85 support level if sentiment turns.
Fundamentally, MSGE’s valuation appears stretched: a trailing PE of 67× versus an industry average of 17× and a price‑to‑book of 91× dwarf peers, while the DCF model implies a fair value of $78.65, offering only about a 9.6% upside. Revenue growth is modest at 1.6% YoY, and operating margins sit at 10%, but the company generates solid free cash flow of $328.7 M against a hefty debt load of $1.19 B, resulting in an alarming debt‑to‑equity ratio above 2,400%. No dividend is paid, and ROE is a weak 1.7%, underscoring the valuation concerns.
Recent earnings showed higher concert‑driven revenue and robust suite sales, yet adjusted operating income slipped due to rising costs, prompting mixed analyst sentiment despite a consensus “buy” rating and target price lifts to the mid‑$70s. The market sentiment is at “Extreme Greed” on the Fear & Greed Index, reflecting optimism that may be pricing in future growth from venue bookings and the Christmas Spectacular. However, the combination of high valuation multiples, elevated leverage, and overbought technicals suggests caution, with upside more likely to materialize over a medium‑term horizon as the company improves margins and reduces debt.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI in overbought territory near resistance
  • Recent earnings beat but rising cost pressures
  • High valuation multiples limiting near‑term upside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF fair value indicates ~9% upside
  • Forward EPS growth and improving revenue mix
  • Analyst target revisions moving higher

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strategic venue portfolio provides stable cash flows
  • Elevated debt load may constrain future returns
  • Absence of dividend and weak ROE limit total return potential

Key Metrics & Analysis

Financial Health

Revenue Growth1.60%
Profit Margin4.81%
P/E Ratio67.3
ROE170.32%
ROA5.02%
Debt/Equity2473.06
P/B Ratio91.0
Op. Cash Flow$341.0M
Free Cash Flow$328.7M
Industry P/E17.1

Technical Analysis

TrendBullish
RSI67.3
Support$59.85
Resistance$70.81
MA 20$66.56
MA 50$62.12
MA 200$53.02
MACDBullish
VolumeIncreasing
Fear & Greed Index91.5

Valuation

Fair Value$78.65
Target Price$76.00
Upside/Downside9.56%
GradeOvervalued
TypeBlend

Risk Assessment

Beta0.93
Volatility26.03%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.